Excessive growth of non-sensitive bacteria (overgrowth of non-susceptible organisms)
Patients taking Amovin are at an increased risk. Prolong use of Amovin treatment may develop excessive growth of non-sensitive bacteria against medicines.
Patients taking allopurinol
Such patients are at an increased risk when using Amovin. These patients may develop an allergic skin reaction.
Patients with amoxicillin sensitive bacterial (amoxicillin-susceptible organism) infection
Patients with amoxicillin-susceptible organism are at increased risk when using Amovin. Amovin may cause an infection in such patients. Changing Amovin therapy to only amoxicillin therapy should be recommended after proper clinical guidance.
Abnormal functioning of the kidney
Patients with abnormal functioning of the kidney or taking higher doses of Amovin are at an increased risk when using Amovin. Use of Amovin in these patients may cause convulsions. Dose adjustment is recommended in such patients.
Development of drug-resistant bacteria
Using Amovin in the improper diagnosis of bacterial infection may cause the development of resistance in bacteria for the drug.
Microbial overgrowth
The patients who are using Amovin are at an increased risk of occurrence of superinfections caused by bacterial or fungal pathogens. If superinfection occurs, discontinue the use of Amovin.
Patients with mononucleosis (an infectious condition caused by virus)
Such patients are at an increased risk when using Amovin. Amovin cause redness of the skin (erythematous skin rash) in patients with
mononucleosis. Such patients should not use this medicine.
Clostridium difficile associated diarrhea
The patients using antibacterial drugs are at increased risk while using this medicine. The use of Amovin may cause mild
diarrhea to possibly fatal
colitis. Antibacterial agents alter the organisms present in the colon causing overgrowth of the Clostridium difficile bacteria. If Clostridium difficile associated diarrhea (CDAD) occurs discontinue the use of Amovin. The suitable treatment for treatment of this kind of diarrhea includes an appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment, and surgical evaluation as clinically indicated.
Abnormal functioning of the liver
Such patients are at an increased risk when using this medicine. These patients may experience conditions such as abnormal functioning of the liver, inflammation of the liver (
hepatitis), decrease in bile flow from liver (
cholestatic jaundice) and fatal conditions due to liver failure. Precaution in dose adjustment and regular monitoring of liver function is recommended in patients with abnormal functioning of the liver.
Allergic to Amovin
Patients with a history of allergic reactions to penicillins, cephalosporins, allergens or receiving beta-lactam antibacterials are at an increased risk when using Amovin. Such patients may experience life-threatening allergic reactions (anaphylactic) reactions. Before starting the treatment with Amovin, careful analysis is required regarding previous allergic reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue the use of Amovin.
Patients with blisters and red, scaly rash with bumps under the skin (acute generalized exanthemous pustulosis)
The patients with these skin conditions are at increased risk when using this medicine. Using Amovin may cause
fever and
blisters with red, scaly rash and bumps under the skin (feverish generalized erythema) along with pus-containing blisters (pustula) in patients with acute generalized exanthemous pustulosis. Patients should stop or avoid taking Amovin on the occurrence of feverish generalized erythema with pustules.
Use of anticoagulants with Amovin
Patients taking
anticoagulants with Amovin are at increased risk when using this medicine. These patients may experience increased
bleeding time (prothrombin time). Careful monitoring and dose adjustment of anticoagulants are recommended in patients using Amovin.
Patients with reduced urination
Patients with reduced urination are at increased risk when using Amovin. Using Amovin in patients with reduced urine output may cause cloudiness due to
crystals in the urine (crystalluria) when taken parenterally. Appropriate fluid intake and excretion of urine are recommended in patients. A regular checkup is necessary for patients with bladder catheters.
Urine glucose test
Using Amovin may cause false positive results during a urine glucose test. Use enzymatic glucose oxidase methods for testing of the presence of glucose in urine.
False positive Coombs test
Using Amovin may cause a non-specific binding of antibody and protein (IgG and albumin respectively) due to the presence of clavulanic acid which may result in a false positive Coombs test.